Of note, malignant cells isolated from such lymphomas become sensitive to OXPHOS inhibitors, suggesting that targeting OXPHOS and EGR1, either separately or in combination, may prove efficacious in patients with lymphomas overexpressing EGR1. This evidence concerns the gene EGR1 and lymphoma.